ENLV
Enlivex Ltd.
A clinical-stage biopharmaceutical company developing Allocetra, an immunotherapy made from dying (apoptotic) cells that helps retrain the body's immune system to stop attacking healthy tissue. Its lead programs target sepsis and osteoarthritis, and it was formerly known as Enlivex Therapeutics Ltd. The company is based in Israel and works with researchers worldwide to bring this cell-based therapy to patients.
CINS: M4130Y106HealthcareIL1 holder
Jul 9, 2026 — Reclassified as ENLIVEX LTD (0.0666667 shares per share)
Total Value
$1.31M
Total Shares
2.38M
Net Share Change
+1.75M
Activity
1 buying
Investor
Value
Shares
Weight
Change
